CRIS Current Research Information System

FUSAROLI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.090
NA - Nord America 1.785
EU - Europa 1.475
SA - Sud America 191
AF - Africa 103
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.730
CN - Cina 956
SG - Singapore 794
IT - Italia 707
VN - Vietnam 509
HK - Hong Kong 251
KR - Corea 167
BR - Brasile 145
IN - India 128
DE - Germania 126
NL - Olanda 109
BD - Bangladesh 84
SE - Svezia 83
GB - Regno Unito 75
FR - Francia 67
JP - Giappone 65
FI - Finlandia 51
RU - Federazione Russa 50
CA - Canada 36
CI - Costa d'Avorio 36
IE - Irlanda 35
ID - Indonesia 32
AT - Austria 28
AR - Argentina 25
BG - Bulgaria 25
CH - Svizzera 24
TG - Togo 21
ES - Italia 20
ZA - Sudafrica 20
AU - Australia 16
TH - Thailandia 15
TR - Turchia 15
IQ - Iraq 14
PL - Polonia 14
GR - Grecia 10
PH - Filippine 10
SA - Arabia Saudita 10
BE - Belgio 9
MX - Messico 9
MY - Malesia 9
PT - Portogallo 9
NZ - Nuova Zelanda 8
UA - Ucraina 7
CO - Colombia 5
JO - Giordania 5
KE - Kenya 5
LT - Lituania 5
NG - Nigeria 5
PK - Pakistan 5
TW - Taiwan 5
EC - Ecuador 4
EG - Egitto 4
HU - Ungheria 4
JM - Giamaica 4
NP - Nepal 4
PE - Perù 4
RS - Serbia 4
BA - Bosnia-Erzegovina 3
CL - Cile 3
GH - Ghana 3
MA - Marocco 3
SC - Seychelles 3
VE - Venezuela 3
CZ - Repubblica Ceca 2
HN - Honduras 2
IL - Israele 2
KZ - Kazakistan 2
OM - Oman 2
PY - Paraguay 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
BJ - Benin 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
HR - Croazia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MT - Malta 1
NI - Nicaragua 1
PR - Porto Rico 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 6.669
Salva come PNG Salva come JPEG
Città #
Singapore 559
Hefei 400
Ashburn 260
Hong Kong 236
Bologna 211
San Jose 193
Seoul 162
Ho Chi Minh City 138
Hanoi 130
Council Bluffs 100
Santa Clara 97
Boardman 80
Chandler 74
Beijing 66
Los Angeles 63
Milan 58
Tokyo 50
Dallas 42
The Dalles 41
Lauterbourg 38
Bengaluru 37
Abidjan 36
Dublin 34
Helsinki 34
New York 34
Rome 29
Princeton 28
Jakarta 26
Buffalo 24
Redmond 24
Sofia 24
Southend 24
Da Nang 23
Haiphong 21
Lomé 21
Redondo Beach 21
Shanghai 20
Bern 19
Frankfurt am Main 19
Modena 19
Orem 19
São Paulo 19
Vienna 18
Biên Hòa 15
Munich 15
Turin 14
Guangzhou 13
Amsterdam 12
Chicago 12
Fairfield 12
Florence 12
Johannesburg 12
Nuremberg 12
Tongling 12
Toronto 12
Atlanta 11
London 11
Phoenix 11
Cesena 10
Rimini 10
Bangkok 9
Hangzhou 9
Houston 9
Lappeenranta 9
Naples 9
San Diego 9
Indianapolis 8
Monselice 8
Montreal 8
Nha Trang 8
Paris 8
Poplar 8
San Francisco 8
Seattle 8
Shenzhen 8
Suzhou 8
Xi'an 8
Brussels 7
Can Tho 7
Chengdu 7
Genoa 7
Hyderabad 7
New Delhi 7
Ninh Bình 7
Auckland 6
Berlin 6
Brescia 6
Brooklyn 6
Bến Tre 6
Cambridge 6
City of London 6
Denver 6
Embrun 6
Hải Dương 6
Jinan 6
Lizzano 6
Mercato Saraceno 6
Mexico City 6
Milwaukee 6
Palermo 6
Totale 4.064
Salva come PNG Salva come JPEG
Nome #
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 308
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 289
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 230
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 230
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 215
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 213
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 198
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 198
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 196
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 191
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 183
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 182
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 175
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 172
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency 170
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 169
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 164
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 158
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 145
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 144
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System 138
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 138
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline 137
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 136
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database 126
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 122
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 121
Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list 118
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study 115
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System 113
What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System 110
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 109
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System 108
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system 105
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System 105
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal 97
The evolving role of disproportionality analysis in pharmacovigilance 92
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance 89
Environmental sustainability-an essential component of rational use of medicines 87
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database 77
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system 76
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports A Note of Caution 75
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance” 74
Characterizing post-mortem blood concentrations in methadone-related deaths 72
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System 70
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach 70
Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis 63
Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study 49
Interpretation of Pharmacovigilance Disproportionality Analyses 44
Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology 35
Transparency and robustness of safety signals 25
Totale 6.826
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.238
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.238
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/2022256 1 0 7 10 10 10 36 47 20 21 58 36
2022/2023478 36 19 31 32 48 38 45 48 81 14 54 32
2023/2024420 36 41 41 56 43 60 22 39 15 30 30 7
2024/20251.651 93 139 165 104 129 66 109 129 65 119 175 358
2025/20263.985 406 508 340 301 330 153 586 184 477 243 205 252
Totale 6.826